Ottimo Pharma is a technology company.
Ottimo Pharma has raised $140.0M across 1 funding round.
Ottimo Pharma has raised $140.0M in total across 1 funding round.
Ottimo Pharma is a private biotechnology company developing first-in-class, dual paratopic PD-1/VEGFR2 antibodies for solid tumors, with its lead asset Jankistomig targeting immune checkpoint inhibition (PD-1) and angiogenesis (VEGFR2) in a single IgG therapy to extend patient lives.[1][2][4] Co-founded in 2020 by Medicxi and Jonny Finlay, it emerged from stealth in October 2024, backed by top investors like OrbiMed, Avoro Capital, and others, and is advancing IND-enabling studies for Jankistomig with FDA filing planned for late 2025.[1][2][6] The company serves cancer patients by addressing tumor microenvironment challenges, offering a wider therapeutic window over bispecific fusions through cooperative binding and minimized VEGF side effects.[1][3]
(Note: One source incorrectly describes focus on gastrointestinal diseases, but consensus across primary sources confirms oncology for solid tumors.[5])
Ottimo Pharma was co-founded in 2020 by life sciences investor Medicxi and antibody engineer Jonny Finlay, remaining in stealth until October 2024.[1][2][6] The idea emerged from innovative antibody design to combine PD-1 checkpoint blockade with VEGFR2 angiogenesis inhibition in a novel dual-pathway, single-agent format, leveraging high PD-1 affinity for better immune cell distribution in tumors.[2][3] Pivotal early traction includes assembling a world-class team: David Epstein (former Novartis Pharma CEO and Seagen leader) as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, James Sabry (Medicxi Managing General Partner) as Vice-Chair, with later additions like Roger Dansey (oncology expert) to the board in April 2025 and senior VPs Robert Tighe and Katherine Bell-McGuinn in February 2025.[2][3][4] Jankistomig advanced through three years of preclinical work, culminating in public launch.[6]
Ottimo rides the wave of next-generation cancer immunotherapy, combining checkpoint inhibitors with anti-angiogenesis in multifunctional antibodies amid surging demand for solid tumor therapies post-PD-1/PD-L1 dominance.[1][2][6] Timing aligns with maturing ADC and bispecific platforms, but Ottimo's IgG-based dual paratopic approach differentiates by simplifying administration and safety over multi-agent regimens or fusions.[1][3] Favorable market forces include growing evidence for PD-1/VEGF combos (e.g., research-backed synergies) and investor appetite for oncology, as seen in its stealth-to-Series B trajectory.[2][6] It influences the ecosystem by validating "exquisitely designed" single agents from elite teams, potentially accelerating similar TME-targeted innovations.[1][4]
Ottimo is poised to enter clinical trials with Jankistomig in 2026 post-late-2025 IND, scaling its team and preclinical strategy amid strengthening leadership.[4] Trends like multifunctional antibodies and TME modulation will propel it, with potential Phase 1 data in solid tumors shaping proof-of-concept by 2027-2028. Its influence may grow via partnerships or acquisition (echoing Epstein's Seagen exit), redefining dual-pathway oncology if efficacy holds. This stealth-emergent biotech exemplifies precise innovation extending cancer patient lives.[1][2][6]
Ottimo Pharma has raised $140.0M in total across 1 funding round.
Ottimo Pharma's investors include Arix Bioscience, OrbiMed.
Ottimo Pharma has raised $140.0M across 1 funding round. Most recently, it raised $140.0M Series A in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $140.0M Series A | Arix Bioscience, OrbiMed |